Cargando…
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442042/ https://www.ncbi.nlm.nih.gov/pubmed/37566304 http://dx.doi.org/10.1007/s40123-023-00788-9 |
| _version_ | 1785093500679749632 |
|---|---|
| author | Yanagi, Yasuo Takahashi, Kanji Iida, Tomohiro Gomi, Fumi Morii, Junko Kunikane, Eriko Sakamoto, Taiji |
| author_facet | Yanagi, Yasuo Takahashi, Kanji Iida, Tomohiro Gomi, Fumi Morii, Junko Kunikane, Eriko Sakamoto, Taiji |
| author_sort | Yanagi, Yasuo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10442042 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104420422023-08-22 Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan Yanagi, Yasuo Takahashi, Kanji Iida, Tomohiro Gomi, Fumi Morii, Junko Kunikane, Eriko Sakamoto, Taiji Ophthalmol Ther Correction Springer Healthcare 2023-08-11 2023-10 /pmc/articles/PMC10442042/ /pubmed/37566304 http://dx.doi.org/10.1007/s40123-023-00788-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Yanagi, Yasuo Takahashi, Kanji Iida, Tomohiro Gomi, Fumi Morii, Junko Kunikane, Eriko Sakamoto, Taiji Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_full | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_fullStr | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_full_unstemmed | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_short | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_sort | correction: cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in japan |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442042/ https://www.ncbi.nlm.nih.gov/pubmed/37566304 http://dx.doi.org/10.1007/s40123-023-00788-9 |
| work_keys_str_mv | AT yanagiyasuo correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT takahashikanji correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT iidatomohiro correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT gomifumi correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT moriijunko correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT kunikaneeriko correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT sakamototaiji correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan |